Volume 6, Number 2 (2021)
Year Launched: 2016
Journal Menu
Archive
Previous Issues
Why Us
-  Open Access
-  Peer-reviewed
-  Rapid publication
-  Lifetime hosting
-  Free indexing service
-  Free promotion service
-  More citations
-  Search engine friendly
Contact Us
Email:   service@scirea.org
Home > Journals > SCIREA Journal of Materials > Archive > Paper Information

Controlled Drug Release from Sodium Alginate Film Dosage Forms

Volume 6, Issue 2, April 2021    |    PP. 12-24    |PDF (213 K)|    Pub. Date: May 17, 2021
35 Downloads     270 Views  

Author(s)
Yoshifumi Murata, Faculty of Pharmaceutical Science, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan
Sayaka Kimura, Faculty of Pharmaceutical Science, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan
Kyoko Kofuji, Faculty of Pharmaceutical Science, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan
Chieko Maida, Faculty of Pharmaceutical Science, Hokuriku University, Ho-3, Kanagawa-machi, Kanazawa 920-1181, Japan

Abstract
Film dosage forms (FDs) prepared using water-soluble polymers can efficiently deliver drugs to local disease sites. In the present study, we prepared FDs by incorporating a model drug rebamipide into a film made of sodium alginate (Alg-Na), comprising an alginic acid hydrolysate and α-L-guluronic acid (G) block (G-block), as the film base. The drug immediately dissolved from the FDs prepared with 3%–5% Alg-Na, and the amount Alg-Na in the formulation scarcely affected the drug dissolution profile. The drug dissolution rate decreased, according to the increment in the amount of G-block incorporated into the FD, as the aqueous solubility of the drug decreased after G-block incorporation. The rate did not change after the sodium salt of the G-block was added to the film base. Rebamipide FDs prepared with Alg-Na may be effective for treating oral mucositis, as the drug release rate from FDs can be controlled by modifying the composition of the film base.

Keywords
Film Dosage Form, Alginic Acid Hydrolysate, Rebamipide, Controlled Drug Release, Sodium Alginate

Cite this paper
Yoshifumi Murata, Sayaka Kimura, Kyoko Kofuji, Chieko Maida, Controlled Drug Release from Sodium Alginate Film Dosage Forms, SCIREA Journal of Materials. Vol. 6 , No. 2 , 2021 , pp. 12 - 24 .

References

[ 1 ] K. H. Min, S. F. Sasaki, Y. Kashiwabara, M. Umekawa, and K. Nisizawa, “Fine structure of SMG alginate fragment in the light of its degradation by alginate lyases of Pseudomonas sp,” Journal of Biochemistry, vol. 81, no. 3, pp. 555-562, 1977.
[ 2 ] F. Martínez-Gómez, A. Mansilla, B. Matsuhiro, M. C. Matulewicz, and M. A. Troncoso-Valenzuela, “Chiroptical characterization of homopolymeric block fractions in alginates,” Carbohydrate Polymers, Vol. 146, pp. 90-101, 2016.
[ 3 ] Y. Murata, D. Jinno, D. Liu, T. Isobe, K. Kofuji, and S Kawashima, “The drug release profile from calcium-induced alginate gel beads coated with an alginate hydrolysate,” Molecules, vol. 12, pp. 2559-2566, 2007.
[ 4 ] D. El. Khoury, H. D. Goff, and G. H. Anderson, “The role of alginates in regulation of food intake and glycemia: a gastroenterological perspective,” Critical Reviews in Food Science and Nutrition, vol. 55, no. 10, pp. 1406-1424, 2015.
[ 5 ] S. Ścieszka, and E. Klewicka, “Algae in food: a general review,” Critical Reviews in Food Science and Nutrition, vol. 59, no. 21, pp. 3538-3547, 2019.
[ 6 ] N. Uemura, I. Oda, Y. Saito, H. Ono, J. Fujisaki, N. Matsuhashi, K. Ohata, N. Yahagi, T. Yada, M. Satoh, H. Tajiri, M. Inomata, and S. Kitano, “Efficacy and safety of 0.6% sodium alginate solution in endoscopic submucosal dissection for esophageal and gastric neoplastic lesion: A randomized controlled study,” Digestive Endoscopy, vol. 31, no. 4, pp. 396-404, 2019.
[ 7 ] J. Wilkinson, .K Abd-Elaziz, I. den Daas, J. Wemer, M. van Haastert, V. Hodgkinson, M. Foster, and C. Coyle, “Two placebo-controlled crossover studies in healthy subjects to evaluate gastric acid neutralization by an alginate-antacid formulation (Gaviscon Double Action),” Drug Development and Industrial Pharmacy, vol. 45, no. 3, pp. 430-438, 2019.
[ 8 ] S. Sonmez, C. Coyle, D. Sifrim, and P. Woodland, “Duration of adhesion of swallowed alginates to distal oesophageal mucosa: implications for topical therapy of oesophageal diseases,” Alimentary Pharmacology & Therapeutics, vol. 52, no. 3, pp. 442-448, 2020.
[ 9 ] M. H. Jaafar, S. Z. Safi, M. P. Tan, S. Rampal, and S. Mahadeva, “Efficacy of rebamipide in organic and functional dyspepsia: a systematic review and meta-analysis,” Digestive Diseases and Sciences, vol. 63, no. 5, pp. 1250-1260, 2018.
[ 10 ] H. Tanaka, T. Nakayama, M. Tsukamoto, A. Watanabe, T. Nakamura, N. Yokoi, C. Sotozono, and S. Kinoshita, “Rebamipide promotes lacrimal duct epithelial cell survival via protecting barrier function,” Scientific Reports, vol. 10, no. 1, p. 1641, 2020.
[ 11 ] B. Chaitanya, K. M. Pai, P. H. Yathiraj, D. Fernandes, and Y. Chhaparwal, “Rebamipide gargle in preventive management of chemo-radiotherapy induced oral mucositis,” Oral Oncology, vol. 72, pp. 179-182, 2017.
[ 12 ] S. Akagi, T. Fujiwara, M. Nishida, A. Okuda, Y. Nagao, T. Okuda, H. Tokuda, and K. Takayanagi, “The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis,” Journal of Pharmaceutical Health Care and Sciences, vol. 5, p. 16, 2019.
[ 13 ] A. O. Ferreira, M. A. F. Brandão, F. J. Raposo, H. C. Polonini, and N. R. B. Raposo, “Orodispersible films for compounding pharmacies,” International Journal of Pharmaceutical Compounding, vol. 21, no. 6, pp. 454-461, 2017.
[ 14 ] R. G. Strickley, “Pediatric oral formulations: an updated review of commercially available pediatric oral formulations since 2007,” Journal of Pharmaceutical Sciences, vol. 108, no. 4, pp. 1335-1365, 2019.
[ 15 ] I. Takeuchi, C. Togo, and K. Makino, “Rebamipide-containing film using chitosan and HPMC for oral mucositis induced by cancer chemotherapy,” Anticancer Res, vol. 39, no. 12, pp. 6531-6536, 2019.
[ 16 ] Y. Murata, Y. Maejima, C. Maida, and K. Kofuji, “Disintegration properties and drug release profiles of chondroitin sulfate films,” SCIREA Journal of Materials, vol.4, no. 2, pp. 32-40, 2019.
[ 17 ] Y. Murata, C. Maida, and K. Kofuji, “Drug release profiles and disintegration properties of pectin films,” Materials vol. 12, no. 3, pp. 355-361, 2019.
[ 18 ] Y. Murata, C. Maida, and K. Kofuji, “Disintegration properties and drug release profiles of sodium alginate films containing rebamipide,” Research & Development in Material Science, vol. 15, no. 1, pp. 1635-1639, 2021.
[ 19 ] C. Gijare, and A. Deshpande, “Orodispersible films: a systematic patent review,” Recent Patents on Drug Delivery and Formulation, vol. 12, no. 2, pp. 110-120, 2018.
[ 20 ] A. Haug, B. Larsen, and O. Smidsrod, “Uronic acid sequence in alginate from different sources,” Carbohydrate Research, vol. 32, pp. 217-225, 1974.
[ 21 ] S. Sonawane, and P. Gide, “Optimization of forced degradation using experimental design and development of a stability-indicating liquid chromatographic assay method for rebamipide in bulk and tablet dosage form,” Scientia Pharmaceutica, vol. 79, no. 1, pp. 85-96, 2011.